The Honest Dose #19

Last issue was all altitude. The hundred million dollar number, the enforcement wave, the on-chain money map. It’s useful to zoom out like that every so often to get perspective on where our shared interest in peptides sits in the world at large. This week I want to zoom back in and do the thing this newsletter was originally built to do, which is take one compound and look at it honestly, and extensively.

The one I picked, Kisspeptin-10, is a good test case, because it breaks the usual pattern in a way I find interesting. Most gray market peptides fail the same way, a real mechanism doing all the work while the human evidence stays thin to nonexistent. Kisspeptin does not fail there. It has several human trials, run by serious academics, published in prestigious journals. That makes it more challenging to write about than the easy debunks, and more worth writing about, because the honest problem here is not "there is no science." It is that the science is real, small, mostly about a slightly different molecule, and pointed at questions the vendors are not answering. That is a more grown up kind of gap, and it is the one I want to walk through.

Let's get into it.

If you have wandered into the "natural testosterone" or "restart your own hormones" corner of peptide content, you have met Kisspeptin. It gets sold as a gentler alternative to TRT. A libido lever, a fertility or post-cycle restart button, the compound that makes your body do the work instead of replacing the hormone directly. It is one of the more scientifically legitimate names in the catalog. It is also a clean example of how far apart "the research is real" and "the thing you would buy does what they say" can sit.

What it is, and where it sits in the body. Kisspeptin is a signaling peptide encoded by the KISS1 gene. Kisspeptin-10 is the short ten-amino-acid tail of it, the minimum fragment that still switches on the receptor, GPR54 (also called KISS1R). What that switch controls is the top of the reproductive chain, the hypothalamic-pituitary-gonadal axis. Kisspeptin tells the GnRH neurons to fire, GnRH tells the pituitary gland to release LH and FSH, and those tell the gonads to make testosterone or drive ovulation. So Kisspeptin does not add a hormone. It sits one rung above the switch that starts the whole cascade and gives it a little push.

Why the "natural TRT" framing is upside down. Because it works upstream, Kisspeptin only does anything if the chain below it is intact. Responsive GnRH neurons, a working pituitary, functional gonads. If the reason your testosterone is low lives in the testes themselves, pushing the top of the ladder harder does nothing, because the bottom rungs are broken. This is the opposite of testosterone replacement, which works precisely by skipping the chain and delivering the hormone directly. Selling Kisspeptin as "TRT but natural" describes a compound for people who mostly do not need it and quietly excludes the people TRT is actually for. The mechanism is real. The sales framing has it pointed the wrong way.

The human research is real, which is rare, so give it its due. Intravenous Kisspeptin-10 in healthy men has been shown to increase the frequency of LH pulses in a dose-dependent way, roughly from about one pulse every hour and a half to a bit more than one an hour, and to raise testosterone alongside it. There is work in women with hypothalamic amenorrhea, where the axis has gone quiet. There is a real body of careful physiology here. For a compound you can buy from a gray-market vendor, that’s unusual, and I am not going to pretend otherwise. This is not a compound relying entirely on anecdotes.

Now the name bends. Almost all of the headline-grade human results, the ones that make Kisspeptin sound like a breakthrough, were run on Kisspeptin-54, the full-length molecule, not the -10 fragment in the vial. The IVF work, where a single dose of Kisspeptin triggered egg maturation with essentially no severe ovarian hyperstimulation in high-risk women, was -54. The sexual-brain and low-desire imaging studies were predominantly intravenous Kisspeptin-54. And the two forms are not interchangeable. Kisspeptin-54 has a half-life around twenty-eight minutes and appears to reach the brain; Kisspeptin-10's half-life is about four minutes, and the evidence suggests it crosses into the brain far less readily. When they were compared head-to-head in men, the picture was messy, and in at least one study a subcutaneous bolus of Kisspeptin-10 failed to move gonadotropins at all. So the compound doing the impressive science and the compound being sold are relatives, not twins, and the more impressive relative isn’t for sale.

The delivery problem finishes it. That four-minute half-life is not a footnote. The research that makes Kisspeptin-10 look active used intravenous infusion in a clinical setting. A short-lived peptide injected under the skin at home is not reproducing that, and the one comparison that tested exactly that route came up empty. Layer on tachyphylaxis, the well-documented tendency of this receptor to go quiet under continuous or repeated stimulation, and "more and longer" does not mean stronger, it can mean the signal fades out. The molecule that behaves beautifully in an IV drip is a much less predictable object in a subcutaneous self-injection.

One more limitation that the RQS actually weighs. Nearly the entire Kisspeptin clinical program traces back to a single research group at Imperial College London. That group does excellent work, and this is not a knock on them. It is a structural fact about the evidence: important findings need independent teams to reproduce them before the field can lean on them, and that broad replication has not happened yet. There is no completed Phase 3 trial, no approved Kisspeptin product, and no Phase 3 filing as of 2026. Real science, but early stage and narrow provenance.

The score. Kisspeptin-10 sits at 47 on the Research Quality Score, in the Limited band. This is not Limited-because-empty. It is Limited because the human evidence is small, short, built on surrogate readouts like LH pulses and brain imaging rather than durable real-world outcomes, concentrated in one lab, and largely earned by a different molecular form than the one being sold. Good science and a weak buying case are not a contradiction here, they are the story. As always, the RQS grades research quality and nothing else. It is not a safety rating, not an efficacy rating, and not me telling you whether this works.

RQS: 47/100 - Limited Evidence

Read the full Kisspeptin-10 profile

The claim: Modern food is depleted, everyone is running low on something, and the responsible move is to cover your bases with a daily multivitamin or a stack of the popular ones, magnesium, D, a B-complex, fish oil, whatever the current list is. Take them every day, forever, because you cannot really overdo vitamins and you might be missing something. The promise is insurance: fill the gaps, optimize the machine, prevent the slow diseases before they start.

The reality: There is a real thing buried in here, which is exactly why the overreach works. Some people are short on specific nutrients, and correcting a true deficiency is important. But the claim takes that real, narrow fact and inflates it into "everyone, everything, every day," and that version does not survive contact with the evidence.

Start with the top-line question, does a broad daily supplement actually buy the health it promises for a normally-fed person. About one in three US adults takes a multivitamin, most of them specifically to prevent disease. In 2024 the National Cancer Institute published an analysis of nearly 400,000 generally healthy US adults followed for more than two decades, and found no association between regular multivitamin use and a lower risk of death. The US Preventive Services Task Force, looking at the trial evidence, landed on "insufficient evidence" to recommend for or against. The honest summary is that for a generally well-nourished adult, a daily multivitamin has not been shown to help you live longer or dodge the big chronic diseases. It is mostly topping up things you already have enough of, and the water-soluble surplus is simply excreted.

The "you can't overdo it" line is wrong. You can. The fat-soluble vitamins, A, D, E, accumulate rather than flush, and real harm from over-supplementation is a documented clinical problem, not a theoretical one. Stacking a multivitamin on top of fortified foods and individual pills is how people quietly push past the point of benefit into the range where the extra does nothing good and occasionally something bad.

None of that means supplements are pointless, which is the other ditch. Targeted supplementation for a real gap is useful, and the gaps that are actually common are a short list, not the whole shelf. Vitamin D if you get little sun. B12 for older adults, vegetarians, and vegans, because absorption is a real issue. Folate in pregnancy. Iron for people who are menstruating heavily or already low. Omega-3s if you never eat fish. The pattern is the same every time: find the specific thing you are short on, ideally by testing, and fix that one thing. That is a completely different activity from swallowing a broad stack on the theory that more inputs must mean more health.

And here is a correction I found most interesting. The dose on almost all of this is one-size-fits-all, and the "one size" is essentially a healthy young adult. A twenty-five-year-old and a seventy-five-year-old buy the same gummy at the same amount, and the assumption underneath, that a body's nutrient needs are fixed across a lifetime, is just false. They shift with age, and not all in one direction. B12 absorption drops as the stomach changes with age, so the requirement for the supplemental form actually goes up. The skin makes less vitamin D. Protein needs rise. Meanwhile iron needs fall sharply after menopause, and extra iron becomes a liability rather than a help, and the same accumulation risk on the fat-soluble vitamins gets less forgiving in an older body. So the real problem is not "take more" or "take nothing." It is that the dose has been decoupled from the person taking it, and the research on what older adults specifically should be taking, and how much, is thin. The people most likely to have a real deficiency are being handed a number calibrated for someone forty years younger.

The honest version of the claim: For most well-fed adults, a broad daily stack is buying insurance against a shortfall you probably do not have, at a dose set for somebody else's body, with no demonstrated payoff on the outcomes that actually matter. The version that works is narrow and boring: figure out the handful of nutrients where a real gap is plausible for you, confirm it where you can, correct that, and skip the rest. It is the same calibration problem as last issue, just wearing different clothes. There, buyers were verifying too little about a risk they could measure. Here, people are supplementing a lot without knowing whether they need any of it. Both are the machinery of doing something that feels like health without checking whether it is.

I would like to put Kisspeptin-10 next to Gonadorelin this week, because the market sells them as two flavors of the same idea, "support your own axis instead of replacing the hormone," and the RQS shows they are not standing on similar ground.

Kisspeptin-10 scores 47, Limited. Gonadorelin scores 77, Moderate. On a shelf they look interchangeable. Both act on the reproductive axis, both get pitched for testosterone and fertility, and biologically they are almost neighbors, Kisspeptin sits one rung above the switch that releases GnRH, and Gonadorelin essentially is GnRH. If anything, Kisspeptin's upstream position makes it sound like the more sophisticated tool. The thirty-point gap says the sophistication of the mechanism is not what the score is measuring.

Gonadorelin lands higher because it has the deeper and longer human record. It is a molecule with real clinical history and established diagnostic use, studied across decades and populations, with a well-characterized effect on the pituitary. Kisspeptin, as the lead laid out, has real human data too, but it is younger, smaller, built on surrogate endpoints, concentrated in a single research group, and, critically, largely earned by the -54 form rather than the -10 fragment on sale. Same axis, same sales pitch, very different evidentiary maturity. There is even a head-to-head study in men that put intravenous kisspeptin-10, kisspeptin-54, and GnRH side by side, and the plain GnRH signal was the strongest and most reliable of the three, which is a quiet way of saying the upstream, more exciting-sounding option is not automatically the better-supported one.

That is the instrument doing its job. The RQS does not reward a compound for having a cooler mechanism, for sitting higher in the cascade, or for a compelling "work with your own body" story. It grades how good the human research is, and by that measure the newer, upstream, better-marketed compound is the less-established one. The number measures research quality and nothing else. Not safety, not efficacy, not a verdict on whether either one works.

Compare the axis compounds on the methodology page

The FDA's latest enforcement sweep moved past GLP-1s and into the boutique peptides. On September 1st the agency posted a fresh cluster of warning letters, dated August 24, to online peptide sellers, and the notable part is not that it happened but what got named. Alongside the usual semaglutide and tirzepatide, the letters cite SS-31, PT-141, Tesamorelin, and Ipamorelin blends, plus the bacteriostatic water sold to reconstitute them. This is a different lane than the 503A compounding fight everyone tracks. It is straight unapproved-new-drug enforcement aimed at "research use only" labeling on products clearly meant to be injected. The signal for readers is that the net is widening from the weight-loss headliners to the longevity and performance shelf, and "for research purposes only" on a vial is exactly the phrase the agency is now treating as meaningless.

The next batch of peptides goes before the FDA's advisory committee by early 2027. The July vote that recommended six peptides for the 503A bulks list got all the attention, but two things are worth holding onto. Those six are still not on the final list, meaning they are not yet written into the regulation, so "recommended" still does not mean "legal" or "approved." And a second review is already scheduled before the end of February 2027, this time for LL-37, GHK-Cu, Dihexa, Melanotan II, and PEG-MGF. If you follow this space, that meeting is the next real inflection point, and it is a chance to watch whether the committee's unusually peptide-friendly posture from July holds up against a rougher-looking list.

The supplement industry may soon get fewer warnings on the label, not more. Right as the section above argues that people over-supplement without knowing what they actually need, the FDA is reportedly weighing a relaxation of dietary-supplement warning-label rules, in a country where roughly three-quarters of adults already take at least one supplement. Loosening the on-label cautions on some of the most widely used health products in America, at the exact moment usage and dosing are least matched to the person taking them, is a strange direction, and where it lands is worth tracking. However it resolves, the takeaway does not change: the label was never doing much of the work, and it may soon do even less.

Hopefully that was helpful/interesting, see you next week.

-Emeka

Peptidclear.com

You're receiving this because you signed up at peptideclear.com. No sponsors. No affiliate links. Just the research, translated.